<DOC>
	<DOCNO>NCT00955383</DOCNO>
	<brief_summary>GSK2190915 currently development treatment asthma . This study aim assess safety tolerability single dos GSK2190915 healthy Japanese subject . The study also look pharmacokinetics ( PK ) pharmacodynamics ( PD ) single dos GSK2190915 aim characterise PK/PD relationship healthy Japanese subject . Twelve healthy Japanese subject take part single escalate dose study subject receive one five possible treatment , 10 mg , 50 mg , 150 mg , 450 mg GSK2190915 placebo treatment period . Blood sample ( safety , pharmacokinetics pharmacodynamics ) , urine sample ( safety pharmacodynamics ) ECGs , blood pressure reading , physical examination review adverse event take place number timepoints pre post dose . A minimum 7 day washout treatment period require . Regardless subject completes prematurely withdraw study , follow visit complete 7-10 day follow last dose .</brief_summary>
	<brief_title>GSK2190915 Safety Pharmacokinetic Study Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test 12 lead ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Japanese ethnic origin ( define born Japan four ethnic Japanese grandparent able speak Japanese ) . Male female ( nonchildbearing potential ) 20 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Male subject must agree use one contraception method list Section 8.1 protocol . This criterion must follow time first dose study medication 3 month administration last dose ( far exceed 5 half live administration last dose ) . Body weight equal 45 kg BMI within range 18 28 kg/m2 ( inclusive ) Capable give write informed consent , include compliance requirement restriction list consent form . 12 lead ECG without clinically significant abnormality judge Investigator , QTcB QTcF &lt; 450 msec . Nonsmokers ( never smoke smoking &gt; 6 month &lt; 10 pack year history ( Pack year = ( cigarette per day smoked/20 ) x number year smoke ) ) A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Significant cardiac , pulmonary , metabolic , renal , gastrointestinal abnormality condition opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The detection drug legitimate medical use would necessarily exclusion study participation . The detection alcohol would exclusion screen would need negative predose study . A positive test HIV antibody . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include CYP3A4 inhibitor inducer , vitamin , herbal dietary supplement ( include St John 's Wort ) 14 day screen followup visit , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Hormone Replacement Therapy ( HRT ) permit postmenopausal female . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500mL within 56 day period . Pregnant female determine positive serum hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Japanese</keyword>
</DOC>